ReCode Therapeutics just raised the stakes. The Menlo Park and Durham-based genetic medicines company just closed over $29 million in additional financing, including a fresh $3 million commitment from the Cystic Fibrosis Foundation to drive its RCT2100 program into Phase 2. When a foundation doubles down on top of $25 million already committed across 2023 and 2024, that’s not charity, it’s conviction. That’s money betting on science with teeth.
ReCode Therapeutics is not chasing shiny objects. It’s building therapies for patients the market has ignored. Think cystic fibrosis patients who don’t respond to modulators. Think primary ciliary dyskinesia patients, tens of thousands in the U.S. alone, most undiagnosed. These aren’t “mass markets” by banker logic, but they’re where biotech earns its credibility. Pair that with a delivery system like the Selective Organ Targeting lipid nanoparticle platform, and suddenly “rare” starts looking like ground zero for the next wave of medicine.
Credit where it belongs. Co-founders Daniel J. Siegwart, Ph.D., Philip Thomas, Ph.D., and Michael Torres, Ph.D. cracked open the science with SORT, a fifth-lipid design that sends medicines precisely where they’re needed. CEO Shehnaaz Suliman, M.D., MBA, M.Phil., took that science and put it on rails in 2022. The result is patients dosed in trials across the U.S., U.K., Netherlands, and France. That’s not theory, it’s proof.
Investors have shown up with deep conviction. Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, OrbiMed, Leaps by Bayer, Amgen Ventures, Vida Ventures, Bioluminescence Ventures, and the Cystic Fibrosis Foundation have poured into this company. Across Series A, B, multiple extensions, and foundation support, ReCode Therapeutics has raised about $386 million. That doesn’t happen unless the science stands up under pressure and the clinical path forward is clear.
The next chapter is reach. RCT2100 is pressing ahead in cystic fibrosis. RCT1100 continues its push in primary ciliary dyskinesia. The SORT platform is being extended into central nervous system, liver, oncology, and musculoskeletal targets. That’s not just pipeline building, it’s a signal. ReCode Therapeutics is showing what happens when targeted delivery meets serious capital and a leadership team that knows how to scale.
